Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 13/20 | 0.43 |
| ▸ | MAP2K2 | P36507 | 9/20 | 0.43 |
| ▸ | CSF1R | P07333 | 1/20 | 0.38 |
| ▸ | RAF1 | P04049 | 4/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | BRAF | P15056 | 1/20 | 0.38 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23693716 | 0.92 | MAP2K1 (0.41) | MAP2K1MAP2K2CSF1RRAF1CYP2C9 | |
| SCHEMBL23693713 | 0.90 | MAP2K1 (0.45) | MAP2K1MAP2K2BRAF | |
| SCHEMBL29425299 | 0.90 | MAP2K1 (0.45) | MAP2K1MAP2K2BRAF | |
| SCHEMBL24849642 | 0.90 | MAP2K1 (0.40) | MAP2K1MAP2K2CSF1RRAF1CYP2C9 | |
| SCHEMBL24849658 | 0.89 | MAP2K1 (0.39) | MAP2K1MAP2K2CSF1RRAF1CYP2C9 | |
| SCHEMBL24849400 | 0.89 | CSF1R (0.41) | MAP2K1MAP2K2CSF1RRAF1CYP2C9 | |
| SCHEMBL24849671 | 0.88 | MAP2K1 (0.40) | MAP2K1MAP2K2CSF1RRAF1CYP2C9 | |
| SCHEMBL25720524 | 0.86 | MAP2K2 (0.45) | MAP2K1MAP2K2CSF1RHDAC3HDAC1 | |
| SCHEMBL24848965 | 0.85 | MAP2K1 (0.42) | MAP2K1MAP2K2CSF1RRAF1CYP2C9 | |
| SCHEMBL24927590 | 0.83 | AURKA (0.43) | MAP2K1MAP2K2CSF1RRAF1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230270730-A1 | COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-08-31 | — | — | US | disclosed |
| US-20230002333-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230270730-A1 | COMPOSITION CONTAINING ARYLAMIDE DERIVATIVE | BRAF, NRAS, KRAS | MAP2K1 17/4885MAP2K2 11/4885CSF1R 1365/4885 |
| US-20230002333-A1 | ARYLAMIDE DERIVATIVE HAVING ANTITUMOR ACTIVITY | BRAF, NRAS, KRAS | MAP2K1 162/4885MAP2K2 132/4885CSF1R 1142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.